Transferring big data, such as the genomics data delivered to customers from the Center for Cancer Research Sequencing Facility, has been difficult in the past because the transfer systems have not kept pace with the size of the data. However, the situation is changing as a result of the Globus project.

Scientists who attended the 2015 NCI Intramural Scientific Investigators Retreat on Jan. 13 had a chance to discuss research results with other investigators from across the National Cancer Institute. And this year, they could also explore new possibilities for the future of their research.

A first-of-its-kind drug is showing early promise in attacking certain lung cancers that are hard to treat because they build up resistance to conventional chemotherapy. The drug, CO-1686, performed well in a preclinical study involving xenograft and transgenic mice, as reported in the journal Cancer Discovery. It is now being evaluated for safety and efficacy in Phase I and II clinical trials.

When I started this project, it was not my objective to develop a model for any specific disease, nor did I even suspect that the ultimate result would be some insight into autoimmune disease. The basic research question I was asking was why there are sequences in the 3' untranslated region (3'UTR) of the interferon-gamma (IFN-gamma) mRNA that are more highly conserved than in the coding region of the gene.

Two NCI scientists received the National Medal of Technology and Innovation, the nation’s highest honor for technological achievement. The award was announced by President Obama in October. The honorees, John Schiller, Ph.D., Laboratory of Cellular Oncology (LCO), Center for Cancer Research, NCI, and Douglas Lowy, M.D., also from LCO and NCI deputy director, received their medals at a White House ceremony on Nov. 20.